We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Events

26 Oct 2026 - 29 Oct 2026
16 Nov 2026 - 19 Nov 2026

Portable UTI Molecular Diagnostic Platform Provides Accurate Test Results in 40 Minutes

By HospiMedica International staff writers
Posted on 09 Nov 2022

Despite being one of the most common types of infection Urinary Tract Infections (UTIs) are a comparatively neglected area of medicine. More...

There are no highly accurate diagnostic tools available for point-of-care testing. Currently, the gold standard for UTI diagnosis is to use laboratory culture but this takes at least 24 hours and often involves the transportation of the sample, adding further delay. The absence of fast diagnostic testing means clinicians make treatment decisions based on vague clinical symptoms or inaccurate urine dipstick tests. Now, a rapid and affordable point-of-care molecular diagnostics platform developed specifically to detect bacterial and viral infections aims to change that.

Llusern Scientific Limited’s (Wales, UK) Lodestar DX is a user-friendly, portable molecular platform for testing UTIs and respiratory diseases that provides lab-accurate test results in 30 minutes. The low cost platform technology allows users to conveniently carry out Loop-mediated isothermal amplification (LAMP) reactions. The technique allows amplification and detection of DNA or RNA in a wide range of bacterial and viral targets. Lodestar DX uses an internal algorithm to determine if a LAMP reaction is positive or negative. The algorithm is suitable for use with a wide range of LAMP reactions. The Lodestar DX system outputs the fluorescent reaction data in real time which can be captured directly onto a PC and stored for subsequent off-line analysis. The system can run eight reactions simultaneously and can be operated flexibly based on user needs. It can be operated from the mains supply using its powers adapter or using a 15Vdc source such as a standard vehicle lighter plug, allowing usage in remote settings.

In 2023, Llusern plans to launch a panel of Urinary Tract Infection (UTI) assays including E-coli, Klebsiella and Staphylococcus spp that run on Lodestar DX. Currently undergoing clinical validation, Llusern’s UTI test has a preliminary sensitivity of 95% for E.coli and can detect over 95% of all uropathogens. Easy to use, it does not require sample processing and urine is added directly into the assay tubes for results delivered in 30 minutes. The simple test preparation and ease of use of the Lodestar DX makes it a useful tool in doctor’s offices, clinics and pharmacies. Llusern's molecular diagnostic test for UTIs is a significant step-forward in addressing a huge everyday health problem faced by hundreds of millions of people around the globe.

Related Links:
Llusern Scientific Limited 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Medical Examination & Procedure Light
Vega 80
Patient Monitoring System
AlarmSense
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image Credit: Adobe Stock

Noninvasive Brain-Computer Interface Enables Responses in Some Unresponsive ICU Patients

Cognitive motor dissociation occurs when patients retain signs of consciousness but cannot move or speak to communicate. In the ICU, this hidden consciousness can be difficult to distinguish from coma... Read more

Surgical Techniques

view channel
Image: Half-matched bone marrow transplant expands access to curative treatment for children and young adults with severe aplastic anemia. (Photo courtes of Margarita Dionysiou using Bio Render)

Half-Matched Family Donors Could Expand Transplant Access for Severe Aplastic Anemia

Severe aplastic anemia is a rare, life-threatening disorder in which the bone marrow fails to produce enough healthy blood cells, leaving children and young adults vulnerable to anemia, infection, and bleeding.... Read more

Patient Care

view channel
Image: Researchers evaluated the Omni 128 cm long-axial field-of-view PET/CT system, which captures more of the body and radiotracer signal at once, potentially enabling shorter scans. (Photo courtesy of GE HealthCare)

Total-Body PET/CT Scanner Enables One-Minute Diagnostic-Quality Cancer Imaging

Positron emission tomography/computed tomography (PET/CT) combines radiotracer-based functional imaging with anatomical detail to diagnose, stage, and monitor cancer. Conventional scanners image the body... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.